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ABSTRACT
ANALYSIS AND EXTENSION OF A FLEXIBLE STOCHASTIC DIFFERENTIAL
EQUATION MODEL TO ESTIMATE THE AMOUNT OF NANOCONJUGATES
REQUIRED TO INITIATE REMISSION OF CANCER
Nicholas Skradski, M.S.
Division of Statistics
Northern Illinois University, 2016
Nader Ebrahimi, Director
This thesis examines a definition of reliability that can be applied to targeted
nanoconjugate chemotherapy in cancer and also simulates a stochastic differential equation
model to attempt to predict the estimated time until remission when using targeted
nanoconjugate chemotherapy utilizing a recursive algorithm to attempt to find the dose of
nanoconjugates that will result in remission by an expected time t. Areas of research that can be
used to obtain model parameter values are cited and values for the dose of nanoconjugates, given
as number of nanoconjugates, are predicted for several different model parameters. The model is
then extended to include a probabilistic framework that allows for a prior distribution to be
placed on parameters where the exact value is not known but a distribution of the parameters
may be known. Following that, examples of the extended model are given assuming that all of
the model parameters are random. It is then suggested that the model undergoes evaluation with
empirical data in order to examine the predictions of the model under certain parameters and
some examples of further model extension are given that may allow for better predictions by
relaxing some assumptions. Lastly the code for the program, written in R, is given in the
appendix.
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CHAPTER 1
INTRODUCTION
1.1 - Background
In the past several decades there has been a significant increase in the research into
nanoparticles and their possible applications. These applications are numerous, ranging from use
in electronics, biological experiments (De, Ghosh, & Rotello, 2008; Miranda, Creran, & Rotello,
2010), medicine (Biju, Mundayoor, Omkumar, Anas & Ishikawa, 2010; Lu, Doane, Zhu, &
Burda, 2012), and many other fields. One specifically interesting area of study is the use of
nanotechnology in biomedical applications. Nanomedicine, the approach of science and
engineering at the nanometer scale toward biomedical applications, is the area of study in which
biomedical applications and medicine intersect (Lee, Solanki, Kim, & Jung, 2009). The
biomedical applications are also numerous, ranging from medical imaging (Jain, Huang, ElSayed, & El-Sayed, 2008; Saha, Agasti, Kim, Li, & Rotello, 2012), photodynamic therapy (Celli
et al., 2010; Mansoori, Brandenburg, & Shakeri-Zadeh, 2010), targeted drug delivery (Cai et al.,
2016; Kalomiraki, Thermos, & Chaniotakis, 2016; Keyhanian, Mansoori & Rahimpour, 2010),
bone grafting and regeneration (Murgan & Ramakrishna, 2007; Yang et al., 2016), gene therapy
(Majidi et al., 2016), and multifunctional therapies (Lim et al., 2014). Nanoparticles, through
their novel properties, can produce and improve therapeutics in a variety of different ways
(Doane & Burda., 2012). These ways include improved bioavailability (Aditya et al., 2013) and
improved toxicity to cancer cells, and, as mentioned above, nanoparticles can be used to provide
medicine that can target specific areas of the body. The use of nanoparticles to target specific
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areas of the body is achieved through several methods; these methods include taking
advantage of pH differences in targeted tissues, upregulation or downregulation of receptors in
the cell membranes in targeted tissues, differences in temperature in targeted tissues, and
hydrophobicity changes in targeted tissues (Calixto, Bernegossi, Fonseca-Santos, & Chorilli,
2014; Doane & Burda, 2012). Nanoparticles give the opportunity to utilize more than one of
these methods of targeting at the same time, possibly resulting in much more efficient and
efficacious treatments. The next several paragraphs will provide examples of research that have
utilized nanomedicine targeted treatment methods.
One method of targeted drug delivery utilizes the targeting methods of pH differences
and targeting of upregulated folic receptors in cancer cells, demonstrating that nanomedicine is
not limited to only one method of targeting tissue. For instance, Long et al. (2016) synthesized a
micelle-based targeted treatment by loading cross-linked micelles with doxorubicin and
conjugating folic acid to the fused polymers which would be reactive in lower pH solutions. The
particles were then tested in vitro on mouse fibroblast cells and human cervical carcinoma cells.
It was found that there was significantly more doxorubicin release at a pH of 5.8 (less than 20%
released after 160 hours of incubation) than at a pH of 7.4 (over 50% release at an incubation
time of 160 hours), where a pH of 5.8 is closer to what is exhibited in lysosomes and endosomes
and a pH of 7.4 is what is exhibited in healthy human tissue generally. This suggests that
doxorubicin release by this micelle would be lower when in non-tumor tissue, as tumor tissue
often exhibits lower pH levels than healthy tissue. It was also found that the conjugation of folic
acid to the polymer assisted in the uptake of the micelles into the cells, further demonstrating that
this targeting mechanism showed benefits from both the pH targeting, as there would be less
healthy tissue killed, and from folic acid conjugation, as there was more uptake when the micelle
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was conjugated with folic acid. Overall, there is potential for this particular method of targeted
treatment to deliver chemotherapies to cancer cells.
Another targeted treatment involved conjugating folic acid to PEGylated nanoparticles
with quercetin and testing them on mice in vivo with HeLa cells and with IGROV-1 cells; both
are types of ovarian cancer found in humans (El-Gogary et al., 2014). Both cell lines were also
tested in vitro. It was found, through luminescence in vivo and testing with free folic acid and no
free folic acid in vitro, that folic acid improved uptake of the nanoparticles. Furthermore, the
conjugated quercetin showed as much cytotoxicity in the cancer cells as free quercetin, and
release of quercetin was low in serum, which suggests that much of the quercetin would not be
released until entering a cell or entering cancerous tissue. More research on the use of
PEGylated folic acid nanoconjugates is needed to determine whether they are an effective carrier
of chemotherapeutic agents, yet this study demonstrates potential for another effective targeted
therapy.
These examples, though not anywhere close to exhaustive, serve as a foundation for one
of the current problems that exists in nanotechnology research. That problem is the lack of any
models to demonstrate the reliability of nanotechnology drug delivery systems. Currently it is
not possible to tell, in an empirical manner, which nanoparticles should be pursued beyond the
early stages of testing and which ones are superior drug delivery mechanisms. The next section
will describe this problem in further detail and describe one suggested attempt to solve the
problem. Chapter 2 will describe the method proposed in greater detail.
1.2 – Description of the Problem
There is a lack of consensus on what a reliable nanoparticle-based cancer treatment
system is. This lack of consensus results in problems with designing, assessing, and
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implementing nanoparticle-based cancer treatments. Recently, attempts to define reliability and
establish ways to model it have been implemented (Ebrahimi & Mansoori, 2014; Ebrahimi,
Mansoori, & Skradski, 2016). Specifically, Ebrahimi et al. (2016) suggest that a definition of
reliability for cancer targeting nanoconjugate drugs over time should be a probability function
interpreted as the probability of killing all cancer cells in a targeted tissue at some time t, where
the higher the value of the function at time t, the more reliable the therapy is at time t. This
definition of reliability has yet to be applied by researchers, but it does suggest that the faster a
drug kills all of the cancer cells, the more reliable the drug is. Intuitively, this definition makes
sense; however, there may be confusion because it differs from the definition of reliability
generally used in survival analysis.
Barring possible semantic complaints about the definition of reliability in this context,
modeling the probability of successfully treating cancer at certain points in time is a beneficial
endeavor. To model the time taken to achieve death of all cancer cells, Ebrahimi et al. (2016)
also proposed a stochastic differential equation model for the probability of killing all cancer
cells in a certain amount of time. This model has many parameters and may benefit from a
probabilistic framework.
In this thesis, the model proposed by Ebrahimi et al. (2016) will be examined at different
values. There is no data to use to test this model’s parameters, so examples will need to be used.
It should be noted that the model proposed by Ebrahimi et al. (2016) is a time-dependent
extension of the model proposed by Ebrahimi and Mansoori (2014).
Since it is possible to not know what one or more parameters is, a probabilistic
framework will be incorporated into the model. Specifically, in situations where the parameters
are unknown, it will be assumed that each of the unknown parameters will be a random quantity.
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The outline of the thesis is as follows: In Chapter 2, the model proposed by Ebrahimi et
al. (2016) is going to be introduced in detail. Assumptions, postulates, and examples of the
model will be shown. The goal of Chapter 2 will be to test the model under different parameters
in order to determine how the model should function under certain conditions. This will provide
an estimate on how the nanoparticles should behave if the model is able to successfully make
predictions. In Chapter 3, the model will be extended by making the assumption that the
unknown parameters each follow certain distributions. This will then be tested in order to
determine how the distributions affect the probability of killing cancer cells by some time t.
Furthermore, examples will also be given in order to demonstrate how the model is expected to
work under these conditions.

CHAPTER 2
PROPOSED PHARMACODYNAMIC MODEL
2.1 – Introduction to the Model
Table (2.1) lists the notation used, also given in by Ebrahimi et al. (2016), throughout this
thesis. In table (2.1) nanoconjugate is defined as a molecule tailored from nanoparticles that has
at least one biologically active module. A nanoparticle is simply defined as a particle with
diameter between 1nm and 100nm.
The notation in table (2.1) and the criteria postulated by Ebrahimi et al (2016) results in
the following definition of reliability in drug delivery utilizing nanomedicine:
Let T  Inf {t : I1 (t )  kN (t )  0}, P(t )  P(T  t ).
This suggests that T is the time at which all cancer cells will be killed, a description of the
functions mentioned and the parameter k is in the next section. A higher value of P(t ) implies
that a drug delivery system is more reliable. Specifically, a drug delivery system A is more
reliable than a drug delivery system B if PA (t )  PB (t ), where PA (t ) and PB (t ) are the reliability
functions for system A and system B respectively. In general this definition does not necessitate
that a particular drug delivery system is more reliable at some particular time t, or even for all t;
it does, however, necessitate that the faster the drug delivery system kills all of the cancer cells,
the more reliable it is. This should be sufficient for a basic model of the reliability of a drug
delivery system.
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Table 2.1. Notation Used in the Pharmacodynamic Model.

C

S t 

The number of nanoconjugates injected into the bloodstream containing the drug to be
delivered
The number of nanoconjugates that are at the site of administration at time t

S1 (t )
I1 (t )

The number of nanoconjugates that are in non-targeted tissue at time t

I 2 (t )

The number of nanoconjugates that are in healthy cells at time t

R(t )
d1

The number of nanoconjugates that are removed from the body at time t
The average number of nanoconjugates that penetrate targeted tissues per unit time

d2

The average number of nanoconjugates that penetrate healthy cells in the targeted
tissue per unit time
The average number of nanoconjugates that penetrate non-targeted tissue per unit time

d3

The number of nanoconjugates that are in cancerous cells at time t

d4

The average number of nanoconjugates that are eliminated from non-targeted tissues
per unit time

d*

d1  d2  d3

1

The average number of nanoconjugates that are eliminated from cancerous cells in the
targeted tissue per unit time
The average number of nanoconjugates that are eliminated from healthy cells in the
targeted tissue per unit time
The average number of cancerous cells that are killed per unit time
The average number of cancerous cells proliferation per unit time

2

1
d1*
k
N (t )
n
T
P(t )
E (T )
B j (t )

The average number of cancerous cells being eliminated per unit time (   1 )
Number of nanoconjugates carrying the drug needed to destroy a single cancerous cell
in the targeted tissue
The number of cancerous cells in the targeted tissue at time t
The number of cancerous cells in the tissue at time 0
The first time at which all cancerous cells are killed
The reliability of the nanodrug system ( P(T  t ))
The expected time required to kill all cancer cells
Standard Brownian motion, j  1, 2,3, 4,5

 j (t ) Diffusion coefficient, j  1, 2,3, 4,5
Intensity parameter, j  1, 2,3, 4,5
aj
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2.2 – Proposed Pharmacodynamic Model
The model proposed by Ebrahimi et al. (2016) suggests that a pharmacodynamic model
can be used to predict the reliability of the nanotechnology drug delivery system. This model is
based on the number of nanoconjugates that are injected, the behavior of the nanoconjugates in
the body, and the number of nanoconjugates, on average, required to kill a cancerous cell.
The model is a single compartment model, which is to say that the model proposes an
all-encompassing model in which all tissues are treated as a single system. There is, however, a
parameter to describe the rate at which nanoparticles enter targeted tissues and a parameter to
describe the rate at which the nanoparticles enter non-targeted tissue.
The model, based on a first rate elimination process, is mathematically complex due to
the use of a series of stochastic differential equations. Much of the derivation of the equations
can be seen by reading Ebrahimi et al. (2016).
The model begins by assuming that the following four differential equations are used to
model the elimination of nanoconjugates from the body, as given by Ebrahimi et al. (2016):

dS (t )  (d1S (t )  d2 S (t )  d3S (t ))dt ,

(2.1)

dS1 (t )  (d3S (t )  d4 S1 (t ))dt,

(2.2)

dIi (t )  (di S (t )   i Ii (t ))dt, i  1,2,

(2.3)

dR(t )  ( 1I1 (t )   2 I 2 (t )  d4 S1 (t ))dt.

(2.4)

Utilizing basic differential equations concepts, and then setting S (0)  C the following
solutions can be found for Eqs. (2.1)-(2.4):

S (t )  S (0)exp(d *t ),

(2.5)

9

R(t )  C[1 

S1 (t ) 

Cd3
(exp(d 4t )  exp(d *t )),
d *  d4

(2.6)

I i (t ) 

Cdi
(exp(  i t )  exp (  d *t )),
*
d i

(2.7)

d
d1
d
exp( 1t )  * 2 exp( 2t )  * 3 exp(d 4t ) 
d  1
d 2
d  d4
*

(2.8)

d
d
d
(1  * 1  * 2  * 3 ) exp( d *t )].
d   1 d   2 d  d4

Since variation is always observed in effectiveness of medical treatments, in order to
model the rates of the nanoconjugates being removed from the body, stochastic perturbation
terms were introduced into Eqs. (2.1), (2.2), and (2.3). The resulting equations are as follows:
dS (t )  (d *S (t ))dt  1 (t )dB1 (t ),

(2.9)

dS1 (t )  (d3S (t )  d4 S1 (t ))dt   2 B2 (t ),

(2.10)

dIi (t )  (di S (t )   i Ii (t ))dt   i 2 (t )dBi 2 (t ), i  1,2.

(2.11)

The solutions to Eqs. (2.9), (2.10), and (2.11) are as follows:
t

S (t )  C exp(d *t )   exp(d * (t   )) 1 ( )d 
0

S1 (t ) 

Cd3
(exp(d 4t )  exp(d *t )) 
*
d  d4

t
d3
[
exp(  d 4 (t   )  exp(d * (t   )) 1 (  ) dB1 (  )] 
*

0
d  d4



t
0

(2.12)

exp(d 4 (t   )) 2 (  )dB2 (  ),

(2.13)
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I i (t ) 

Cdi
(exp( i t )  exp(d *t )) 
d* i

t
di
[  (exp(   i (t   ))  exp(d * (t   )) 1 (  )dB1 (  )] 
d i 0
*

t

 exp( (t   ))
i

0

i2

(2.14)

(  )dBi  2 (  )i  1, 2.

Since C  R(t )  S (t )  S1 (t )  I1 (t )  I 2 (t ), it is unnecessary to model R(t), as it can be found by
modeling the other parameters. Also, the amount of nanoconjugates in non-targeted tissue is not
important for this model, so S1(t) and I2(t) do not need to be modeled. Ebrahimi et al. (2016)
described the following stochastic differential equation for N (t ) as:

dN (t )   N (t )  1N (t )   5 (t )dB5 (t ).

(2.15)

The solution for N (t ) derived utilizing stochastic calculus concepts is:
t

N (t )  n exp(d1*t )   exp(d1* (t   )) 5 (  )d  ,
0

t

Cov( N (t ), N (t  s))  exp(d1*s)   52 (  )exp(2d1* (t   ))d .
0

(2.16)
(2.17)

If i  1, then the equation for I i (t ) becomes:

I1 (t ) 


Cd1
(exp( 1t )  exp(d *t ))
*
d  1

t
d1
[  (exp( 1 (t   ))  exp(d * (t   )) 1 (  )dB1 (  )]
d  1 0
*

(2.18)

t

  (exp( 1 (t   )) 3 (  )dB3 (  ).
0

Throughout this chapter, for simplicity, it is assumed that  j (t )  exp(a j t ) j , j  1, 2,3, 4,5.
This results in the following covariance for I1 (t ) :
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Cov( I1 (t ), I1 (t  s ))  (

 32

2(a3   1 )

) exp(  1s )(exp(2 1t )  exp(2a3t )) 

d1 1 2 exp(2d *t )  exp(2a1t )
( *
)[
exp(d * s) 
*
d  1
2(a1  d )
exp(2 1t )  exp(2a1t )
exp( 1s ) 
2(a1   1 )

(2.19)

exp((d *   1 )t )  exp (2a1t )
(exp( d s )  exp( 1s ))
].
2a1  (d *   1 )
*

The assumption  5 (t )  exp (  a5t ) 5 reduces Eq. (2.9) to the following:
Cov( N (t ), N (t  s))   52

exp(2d1*t )  exp(2a5t )
exp(d1* s).
2(a5  d1* )

(2.20)

These functions taken together suggest that I1 (t )  kN (t ) is a Gaussian process with mean
A(t ) 

Cd1
(exp( 1t )  exp(d *t ))  kn exp(d1*t ),
d *  1

(2.21)

and covariance
B(t , t  s)  Cov( I1 (t ), I1 (t  s))  k 2Cov( N (t ), N (t  s)).

(2.22)

The estimated probability density function is then:

p(t )  g (t )(2 B(t , t ))

1/2

A2 (t )
exp(
),
2B(t , t )

(2.23)
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where g (t ) is the following:

 52
g (t )   A(t )( B (t , t )) 1 k 2
[(2a5  d1* ) exp( 2a5t )  d1* exp( 2d1*t )] 
*
 2a5  2d1

 32

2a3  2 1

[(2a3   1 ) exp(2a3t )   1 exp(2 1t )] 

2

 d1 1 
1
[(2a1  d * ) exp(2a1t )  d * exp(2d *t )] 
 *

*
 d   1  2a1  2d
2

 d1 1 
1
[(2a1   1 ) exp(2a1t )   1 exp(2 1t )] 
 *

 d   1  2a1  2 1

(2.24)

2

 d1 1 
1
[(2a1  d * ) exp(2a1t )   1 exp((d *   1 )t )] 
 *

*
 d   1  2a1  (d   1 )
2
 d
 d1 1 
1
*
*
[(2
a


)
exp(

2
a
t
)

d
exp(

(
d


)
t
)]
  ( A(t )).
 *

1
1
1
1
*
 d   1  2a1  (d   1 )
 dt

For further details regarding proofs, see Ebrahimi et al. (2016) and the sources referenced. With
this, the probability that all of the cancer cells are killed at a certain time t can be obtained by
integrating the probability density function:
t

P(t )   g ( x)(2 B( x, x))1/2 exp(
0

 A2 ( x)
)dx
2 B( x, x)

(2.25)



The expected value of the function follows intuitively by integrating  x f ( x) I[0, ) ( x)dx, where


I(x) is an indictor function, to obtain:


E (T )   xg ( x)(2 B( x, x))1/2 exp(
0

 A2 ( x)
)dx.
2 B( x, x)

(2.26)

The integral is very complex and has no closed form. Thus, numerical integration techniques
will have to be used.
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With these equations it is possible to determine an algorithm to compute the expected
number of nanoconjugates (C) needed to kill all cancer cells by some time t. Ebrahimi et al.
(2016) suggest a simple iterative algorithm that adds or subtracts from C until it finds a C that
has the closest expected value E(t )   where α is chosen by the experimenter. Here an
algorithm is presented that converges on the same number but obtains the required number
faster, especially if the value of C required to kill cancer cells by time alpha is very far from the
starting point. More specifically, the algorithm proposed adds some number v to the number of
nanoconjugates if E (T )   and subtracts some number, v, of nanoconjugates if E (T )   ,
where v is assumed to be a power of 10. After a number is found such that C-v and C satisfy
E (T )   and E (T )   v is then divided by 10 and then the algorithm is run repeatedly until the

algorithm produces E (T )   and v  1. Finally, the value for C is given when this is finished.
The main idea is that this algorithm will be useful in predicting the estimated number of
nanoconjugates, C, required to kill all cancer cells by time t by testing different values for C.
The implementation of this algorithm in R is given in the appendix.
Due to of a lack of explicit research focusing on some of the parameters, there may
currently be no justification for specific values of the parameters. However, some research does
exist that may give some information about the parameters. For instance, there are studies on
rats that found the relative amount of nanoconjugates distributed to different organs in vivo and
ex vivo (El-Gogary et al., 2014; Patra et al., 2008, Tang et al., 2013). These studies are usually
limited to testing postmortem, testing using fluorescence, or testing using ex vivo methods, but
they may give some insight into the rates at which nanoconjugates are entering untargeted and
targeted tissues. Furthermore, cancer proliferation and growth has been studied extensively
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(Hanahan & Weinberg, 2000; Hannhan & Weinberg, 2011; Jennings, Winer-Muram, Tann,
Ying, & Dowdeswell, 2006; Stein et al., 2010). The next few paragraphs will argue whether or
not values for the parameters can be justified with the current research that is available.
The first parameter that may be justifiable with current research is the number of cancer
cells. According to DeVita et al. (1975), the number of cancer cells in a 1-cm3 tumor is about
one billion cells. This number has been accepted by most medical researchers but has been
questioned in editorials (Del Monte, 2009; Narod, 2012). Overall, since it is known that the
number of cancer cells scales with tumor size, given the ability to measure average sizes of
cancer cells, this parameter would be able to be found by estimating the size of the tumor with
traditional imaging techniques and either accepting the statement by DeVita et al. (1975) as 1
billion cells per cubic centimeter or by analyzing average sizes of different cancers and using
those sizes to predict the number of cells in cancerous tissue.
The second parameter value that may be able to be justified with current research is
growth rate of the cancer being treated. There are studies that attempt to determine growth rates
of different cancers. For instance, Stein et al. (2010) determined an average growth rate of
pancreatic cancers of 0.6cm/year. Also Tseng et al. (2005) determined different growth rates of
prostate cancers prior to treatment and during treatment. Utilizing similar studies to Stein et al.
(2010) and Tseng et al. (2005), it is possible to calculate the growth rates to use in the model.
One objection to the constant growth rate assumption is different models of cancer
growth result in different parameters, and these growth rates are likely not constant
(Ulmschneider & Searson, 2015). For example, Norton (1988) utilizes a Gompertzian model to
model the growth rates of breast cancer, which suggests that the rate of growth is not constant
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over time. This problem can be alleviated in the model proposed by Ebrahimi et al. (2016) by
using the fastest growth rate predicted by the models for the growth rate parameter.
The next parameter to examine is the rate at which cancer cells are killed. In vitro tests
of nanoconjugates suggest that the rate of cancer cell elimination from targeted drug delivery
systems that rely on chemotherapy conjugated with the nanoparticles can be slightly lower than
from free chemotherapy (Long et al., 2016). However, there are some problems with modeling
chemotherapy nanoconjugates that do not exist when modeling traditional chemotherapy
treatments, such as the time of administration differing significantly from the time when the
therapeutic effect of the nanoconjugate is realized. One solution to this problem is a model that
was proposed by Eliaz et al. (2004) that explained the rate of cell elimination when doxorubicin
was encapsulated in liposomes, and the model was tested in vitro on mouse melanoma cells that
were known to overexpress CD44 receptors. Utilizing this model would give the necessary
information to derive the cancer cell elimination rate for at least some nanoconjugates.
Though little research has been done which would allow for a direct computation of the
rate parameters regarding entry into targeted tissues and non-targeted tissues, it may be possible
to estimate it from fluorescence imaging done in vivo or in vitro. For example, El-Gogary et al.
(2014) prepared a targeted drug delivery system with nanoconjugates allowing for fluorescence
which targeted folate-expressing cancer cells. The results, if fluorescence is taken to represent
the amount of nanoconjugates that are inside of the cells of certain body areas, suggest that
targeting the tumor is rather difficult, with much of the drug entering the lungs and the tumor and
to a lesser extent the spleen, kidneys, liver, and heart. There also have been other formulations
of nanoconjugates which enter the targeted tissues far more often, but still less often than other
organs. For example, Comenge et al. (2012) conjugated cisplatin with gold nanoparticles.
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Accumulation was found in the liver, spleen, tumor, and to a much lesser extent, other organs.
This would suggest that in some cases nanoparticles can target other tissues more often than
cancer cells, thus resulting in d3 > d1. Nanoconjugate formulations that result in a higher uptake
by cancer cells than by healthy cells exist as well. For example, Saltan et al. (2011) created a
nanoparticle conjugated with methacrylamido-folic acid that was absorbed by cancer cells at a
higher rate than by healthy cells according to flow cytometic analysis and observations with
transmission electron microscopy. These taken together suggest that there are situations in
which cancer cells uptake nanoparticles at higher rates and at lower rates than healthy cells and
that there are methods to determine the rate of nanoconjugate uptake by healthy and cancerous
tissues.
What follows from the previous paragraph would be an examination of the rate at which
nanoconjugates are removed from cancerous tissue. There is research that suggests that some
nanoconjugates may not clear from the body very well in vivo (Longmire, Choyke, &
Kobayashi, 2008). Furthermore, the enhanced permeability and retention effect, which can be
taken advantage of with nanomedicine, would increase the amount of time nanoconjugates
remain in targeted tissue (Lyer, Khaled, Fang, & Maeda, 2006). Since the enhanced retention
and permeability effect does not present itself in healthy tissue very often, it would follow that
nanoconjugates would filter from healthy tissue faster than cancerous tissue. An example of a
study examining the pharmacokinetic properties of cisplatin and a pectin-cisplatin nanoconjugate
system showed a striking difference between cisplatin and the conjugated cisplatin (Verma &
Sachin, 2008). Specifically, the pectin-cisplatin conjugate had an elimination rate constant of
0.0042 and a half-life of 165 minutes, as opposed to cisplatin alone, which had an elimination
rate constant of 0.0172 with a half-life of 40 minutes, though these numbers were obtained
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without a tumor in the in vivo test. Taken together, this information suggests that the expected
parameter for elimination from cancer cells will be very small, as will the parameter for the
elimination rate from healthy tissue, though the enhanced permeability and retention effect
existing in cancerous tissue more often than healthy tissue would imply that the rate of
elimination from cancerous tissue would be lower than that of healthy tissue.
Another parameter included in the model, the average number of nanoconjugates required
to kill a cancerous cell, is not known for sure, but it is known to scale with the size of the cancer
cell in some cases (Hashemian, & Mansoori, 2013; Keyhanian, Mansoori, & Rahimpour, 2010;
Mansoori, Brandenburg, & Shakeri-Zadeh, 2010; Zharov, Lutfullin, & Galitovskaya, 2005).
This would suggest, though not definitively, that the nanoparticle amount required to kill a
cancer cell should be a function of the cancer cell size.
Overall, it appears to be the case that there is research to draw from which would
determine possible values for the model parameters. Without explicit research to estimate these
parameters, however, it will be difficult to obtain precise values for the parameters.
2.3 – Examples of the Pharmacodynamic Model
The first example here will be a simple example focusing on a very small number of
cancerous cells. Assume that some treatment has already been conducted with traditional
chemotherapy and radiation for some unspecified type of cancer. Assume that there are 210
million cancer cells remaining in the tissue. For numerical stability, the number of cancer cells
and nanoconjugate parameters will be in millions of cells and millions of nanoconjugates.
Further suppose that the targeted drug delivery system has been perfected to such an extent that
nanoconjugates enter the cancerous cells in the targeted tissue with a rate parameter of 1.2
million nanoconjugates per unit time, nanoconjugates enter healthy cells in the targeted tissue
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with a rate parameter of .1 million nanoconjugates per unit time, and nanoconjugates enter nontargeted tissue with a rate parameter of 0.1 million nanoconjugates per unit time. Furthermore,
the amount of nanoconjugates that are eliminated from cancerous cells per unit time is equal to
the amount that enter, and the amount of nanoconjugates that are removed from healthy cells per
unit time equals the number of nanoconjugates that enter healthy cells per unit time. Assume
that the average number of cancerous cells that are killed per unit time is equal to the rate at
which nanoconjugates enter cancer cells per unit time minus .39. Also, assume a cancer growth
rate parameter of .2 and diffusion coefficient parameters of 1  .5, 3  .61, 5  .44 with
intensity parameters a1  0.142, a3  0.0144, a5  0.177. Assume that the cancer cells are fairly
large and only require 15 million nanoconjugates to kill. Using this algorithm it was found that
5223 million nanoconjugates would be required to eliminate the rest of the cancer cells within a
single time unit. The expected nanoconjugates would be required to eliminate the rest of the
cancer cells within half of a time unit would be 7408 million nanoconjugates. Table (2.2) shows
the amount of nanoconjugates required to kill all cancer cells by an expected time t at t=1 and
t=0.5 at different values of k obtained by using the algorithm.
Table 2.2 Expected number of nanoconjugates in millions for example 1 at expected time
until all cancer cells are killed for E(t) = 1 and E(t) = .5 according to the algorithm.
Value of K
5
10
15
20
25
30

Expected number of
nanoconjugates for E(t)=1
1743
3482
5223
6965

Expected number of
nanoconjugates for E(t)=.5
2468
4941
7408
9878

8707
10451

12348
14821
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Again, it is very unlikely that the parameters in this example are accurate or realistic in
vivo. Generally, if cancer is detectable, there would be at least one cubic centimeter of
cancerous tissue, and with the assumption that the cancers are 10 μm in diameter there would be
about one billion cancer cells in the cancerous tissue. Since in this example there were only 210
million cancer cells, unless the cells were larger, this cancer would likely be undetectable.
Furthermore, the diffusion and rate parameters in this example are not necessarily accurate; in
practice it is assumed that these parameters are simply 1 and 0.1 respectively. These problems
could be responded to by suggesting that this treatment is given after traditional chemotherapy
and radiation.
The next example will be far more likely than the previous, at least given the current
information regarding nanomedicine. Assume that a tumor was discovered early and contains
one billion cancerous cells. This would suggest the minimum size is one cubic centimeter.
Furthermore, assume that a1  .12, a3  .11, a5  .2,1  .7, 3  .7, 5  .8,  1  1.2,  2  1.1,

d1  0.9, d2  .1, d3  0.9. This would suggest that targeted tissues are entered as often as nontargeted tissue. Assume   .81, 1  .2. This example is a pessimistic scenario since the rates of
targeted and untargeted tissue being entered by nanoconjugates are the same. There are still
problems, however, as the rate at which nanoconjugates are removed from the tissues is very
high. Table (2.3) provides information regarding how many nanoconjugates would be expected
to kill cancerous cells by t=1 and t=0.5, which were obtained using the algorithm.
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Table 2.3. Expected number of nanoconjugates in millions for example 2 at expected time
until all cancer cells are killed for E(t) = 1 and E(t) = 0.5 according to the algorithm.
Value of K
5
10
15
20
25
30

Expected number of nanoconjugates for
E(t)=1

Expected number of
nanoconjugates for E(t)=.5

11747
23493
35235
46981
58726
70472

16321
32644
48966
65289
81612
97934

The final example will use the same parameters as the previous example; however, the
rate at which nanoconjugates are removed from cancerous and healthy tissues will be much
lower. Assume that  1  0.1,  2  0.2. This appears to be a more realistic representation of
nanoconjugates behavior in vivo since nanoparticles clear from the body slowly and the EPR
effect should reduce the rate at which nanoparticles are removed from cancerous tissue (Lyer et
al., 2006). If this model was realistic, there would be an improvement from a decrease in
estimated time until all cancer cells are destroyed because of the increase in treatment efficacy
due to the EPR effect. This behavior is seen with these examples. Table (2.4) shows this to be
the case. The drop in the rate parameters of nanoconjugate removal from tissues appears to have
a very large effect on the rate of cancer treatment.
Table 2.4. Expected number of nanoconjugates in millions for example 3 at expected time
until all cancer cells are killed for E(t) = 1 and E(t) = 0.5 according to the algorithm.
Value of K
5
10
15
20
25
30

Expected number of nanoconjugates
for E(t)=1

Expected number of nanoconjugates
for E(t)=0.5

7193
14387
21581
28775
35969
43163

13057
26115
39173
52232
65290
78348

CHAPTER 3
EXTENSION OF THE PHARMACODYNAMIC MODEL
3.1 – Introduction and Explanation of the Extension Model
In the previous chapter the model parameters were assumed to be fixed. There may be
benefits to treating the parameters as random since many of them are not known specifically and
current research into nanotechnology is often insufficient to estimate these parameters precisely.
Thus, an estimate based on averaging the parameters over the distribution will be used. If the
parameters of the model are treated as random, they will each follow a distribution which must
be provided in order to model P(t). Under the assumption of independence of every parameter, if
every parameter is treated as random, the joint distribution becomes the following:
t

 P(T  t ) f
0

t

0 



()db 

P( Inf {t : I1 (t )  kN (t )  0}  t | d1 , d 2 , d3 ,  1 ,  3 ,  5 , a1 , a3 , a5 , d1* , n, k ) *



(2.27)

f d1 (d1 ) f d2 (d 2 ) f d3 (d 3 ) f1 ( 1 ) f 3 ( 3 ) f 5 ( 5 ) f a1 (a1 ) f a3 (a3 ) *
f a5 (a5 ) f d * (d1* ) f n (n) f k (k )d dt ,
1

where



...d  represents integrating all parameters of the integral iteratively as well as the



summation of any variables assumed to be discrete. In practice, it may be the case that some of
the parameters are known, in which case there is no need to assign them a distribution, which
would be obtained from experts in the field or derived from studies into the model parameters.
For the following examples, it is assumed that all of the parameters are unknown and that all of
the continuous parameters (d1, d2 , d3 ,1, 3 , 5 , a1, a3 , a5 ) follow an exponential distribution with

22

parameters (v1, v2 , v3 , v4 , v5 , v6 , v7 , v8 , v9 ) respectively. All of the discrete parameters (k , n) follow
a Poisson distribution with parameters (v11 , v12 ) respectively. Since d1* is the difference between
two exponential random variables, it will follow a Laplace distribution truncated at 0 with
parameters (v10,1 , v10,2 ). This satisfies the assumption that the rate of cancer cells being killed is
greater than or equal to the rate that cancer cells are proliferating. The following distribution is
then given when these assumptions are combined with Eq. (3.1):

P(t )  

t





k 0

n 0



0 

g ( x)(2 B( x, x))

1/2

 A2 ( x, x)
exp(
)*
2 B ( x, x )

v1e v1d1 v2e  v2d2 v3e  v3d3 v4e  v41 v5e  v5 3 v6 e v6 5 v7 e  v7 a1 *
v8e v8a3 v9 e v9 a5 v10,1v10,2e

( v10,1  v10,2 1 )

(2.28)

v11k e v11 v12 n e v12
d dx.
k!
n!

This function is 12 dimensions prior to integrating over t, and thus it is extremely
computationally intensive to estimate. In order to compute the integrals, as estimations of the
integral are extremely difficult, Monte Carlo simulation was employed. Fifty thousand randomly
selected values from the prior of each variable were obtained and integration over t was
attempted with them. If integration failed, resampling was done. The variables were resampled
until the assumptions of the model were met, that is, d1*  0,  1  d * ,  2  d *. This was done
because the integral would not converge if these assumptions were not met.
3.2 – Examples of the Extension Model
The first model that was tested was example 1 as seen in Chapter 2. It was assumed that
the parameters followed exponential distributions, the Laplace distribution, and Poisson
distributions with parameters equal to the fixed parameters in example l in Chapter 2. The
specific values for the parameters above are v1  1.2, v2  0.1, v3  0.1, v4  0.5, v5  0.61,
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v6  0.44, v7  0.142, v8  0.0144, v9  0.177, v10,1  0.81, v10,2  0.2, v11  5, and v12  210. The

number of nanoconjugates for E(T) = 1 in example 1 with k = 5 was 1743 million
nanoconjugates. With the new added uncertainty E(T) = 1.1013. This suggests that there will be
an increase in the estimated amount of nanoconjugates required in order to kill all cancer cells
within a single time unit. Table (3.1) shows the expected amount of nanoconjugates in
increments of 50 starting near 1750. Figure (3.1) shows a graph of the expected time to kill all
cancer cells for values of C between 1743 and 2050. What can be seen is that there is an
increase in the expected time until all cancer cells are eliminated at C=1743; as in example 1,
Chapter 2, C=1743 resulted in an expected time of elimination of all cancer cells of E(T)=1. In
the extended model, C=1743 results in an expected time to kill all cancer cells of
E(T)=1.1012596 time units. At C=2050, the expected time to kill all cancer cells was
E(T)=0.7639282 time units.
Table 3.1. Expected time until all cancer cells are killed based on example 1 using the
averaging method with v12=5.
Number of nanoconjugates in millions
(Value of C)
1743
1800
1850
1900
1950
2000
2050

E(T)
1.1012596
1.0285896
0.9602398
0.8915131
0.8395372
0.8028654
0.7639282
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Figure 3.1.
Graph of the estimated time until all cancer cells are killed at differing values of C
based on parameter values from Chapter 2, example 1.
A second example of the extended model will be shown applying the parameters used
previously in Chapter 2, example 3 with k  5. A similar pattern to example 1 was seen in the
expected time for nanoconjugates to kill all cancer cells. The expected number of
nanoconjugates required for E(T )  1 in Chapter 2, example 3 was C=7193. The expected time at
C=7193 nanoconjugates in the extended model, however, was E(T)=1.698633 time units. This
increase suggests that larger uncertainty results in a larger expected minimum number of
nanoconjugates to kill all of the cancer cells by some time t. Table (3.2) shows the expected time
until all cancer cells are killed computed using Monte Carlo integration of the unknown
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parameters. Figure (3.2) shows a graph of the estimated time to kill all of the cancer cells given
a certain value for C.
Table 3.2. Expected time until all cancer cells are killed based on Chapter 2, example 3,
using the averaging method with v12=5.
Number of nanoconjugates in millions
(Value of C)
7000
8000
9000
10000
11000
12000
13000
14000

E(T)
1.698633
1.578399
1.461240
1.372515
1.275146
1.204018
1.169193
1.117799

Figure 3.2.
Graph of the estimated time required to kill all cancer cells for differing values of
C based on parameter values from Chapter 2, example 3.

CHAPTER 4
CONCLUSION AND FUTURE RESEARCH
The model does make some predictions that are in line with the empirical data available.
For instance, the decrease in E(T) when  1 that occurs would be expected due to the EPR effect.
Furthermore, it is easily shown that E(T) decreases in C, which should be the case as an
increased dose of anti-cancer drugs results in higher elimination of cancer cells. Also, there is
research that can be used in order to determine ranges for the parameter values of the model.
Though there are ways to estimate the parameters, currently conclusions are difficult to
draw. Since there is no empirical data to draw upon, it cannot be determined whether or not
these models are useful, or how the models even behave in practice. Further research is required
in order to determine whether or not these models make useful predictions. If predictions are
able to be made, these models will suffice until better models can be derived that provide better
predictions. If the models fail to provide successful predictions, they ought to be discarded and
new models must be formulated in order to make predictions that better match reality. Also, the
model itself is based on several assumptions that may not hold and there may be ways to
improve the model.
First, it is unlikely that the growth rate for cancer is constant. Some research shows that
cancer growth rates follow a Gompertz model in practice (Norton, 1988; Ulmschneider &
Searson, 2015). This problem could be alleviated with the current model by taking the fastest
possible growth rate established by the Gompertz model, but it would result in overestimation of
the rate of cancer growth overall and may cause a useful drug to be deemed not useful under
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certain circumstances, such as a drug that could be used to induce remission prior to a cancer
reaching a certain growth rate. Thus another extension of this model could be done which takes
a non-constant growth rate into consideration.
Second, the model assumes that the nanodrug will kill all of the cancer cells. If all of the
cancer cells are not killed, E(T) will be infinity. This may not be practical because it could be
the case that, at least at the current moment in time, nanodrugs will provide life extension by
slowing the growth rate of the cancer, as is the case with current chemotherapy treatments in
some cases. Thus it appears that this model will only suffice for cases where the treatment of the
cancer may result in remission. It may, however, be the case that nanoparticles can increase the
number of cancers that are able to be put into remission, and as such this model may be useful
when testing nanoconjugates in particular. More research on the applications of nanotechnology
in cancer therapies must be carried out in order to know which future medications this model will
be applicable to.
Third, the model assumes that a single-compartment pharmacokinetic model is sufficient.
Depending on how nanoconjugates behave, this may not be the case. There appears to be a
saturation level (i.e. a level where areas of the body will not uptake any more nanoparticles) and
this saturation level may result in a multi-compartmental model being necessary because it
would likely cause more nanoparticles to remain in the bloodstream. Evidence of this can be
seen in Thurn et al. (2011), where the rate of uptake of the nanoconjugate used followed a
logarithmic pattern.
The current proposed model also uses an approximation for the density (Durbin, 1985).
This approximation may need to be changed because of what appears to be tail behavior
exhibited in this analysis of the model proposed by Ebrahimi et al. (2016). In order to
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circumvent this, the distribution was often truncated and full integration of the distribution may
have resulted in a probability of less than or greater than 1. Generally, unless very high values of
C were used, P(T) was very close to 1. In order to correct for P(T) being unequal to 1, the
expected time until all nanoconjugates were killed was divided by the integral of the density over
the truncated interval. It is unknown whether or not this method would be acceptable when
using this model in practice. Further study of the model is warranted as it appears to be the case
that the approximation from Durbin (1985) may fail in some specific cases.
Last, the stochastic differential equations are assumed to be taken in respect to a standard
Brownian motion. Relaxing this assumption may offer an extension of this model that could
allow for better prediction and estimation. A jump process might be the next step for extension
of this model in terms of stochastic calculus.
Overall, the only way to validate this model is to test it empirically: Treat the model as a
collection of hypotheses, and if the model makes accurate predictions, some of the hypotheses
are correct. Even if the predictions are accurate, there may exist better methods for deriving
models for nanotechnology reliability that have not yet been explored. As such, this model
needs to be first tested against empirical data. If the model is shown to be useful to make
predictions about the reliability of targeted drug delivery, then some of the model’s assumptions
should be relaxed in order to see if better predictions are made, or a better model needs to be
derived using the newly available data. It appears that what must be done regardless of the
performance of the model is further research into reliability of targeted drug delivery utilizing
nanotechnology.
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R CODE USED FOR EXAMPLES IN CHAPTER 2 AND CHAPTER 3
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#Chapter 2
#Covariance function for N(t) Cov(N(t),N(t+s))
CovN = function(t, s=0,sigma,a,d1star)
{
sigma[5]^2*((exp(-2*d1star*t)-exp(-2*a[5]*t))*(2*a[5]-2*d1star)^-1)*exp(-d1star*s)
}
#Covariance function for I(t) function Cov(I(t),I(t+s))
CovI = function(t, s=0, sigma, gamma, a, d, dstar, i=1)
{
sigma[i+2]^2*(2*(a[i+2]-gamma[i]))^-1*exp(-gamma[i]*s)*(exp(-2*gamma[i]*t)-exp(2*a[i+2]*t))+
(d[i]*sigma[1]*(dstar-gamma[i])^-1)^2*((exp(-2*dstar*t)-exp(-2*a[1]*t))*(2*(a[1]-dstar))^1*exp(-dstar*s)+ (exp(-2*gamma[i]*t)-exp(-2*a[1]*t))*(2*(a[1]-gamma[i]))^-1*exp(gamma[i]*s)- (exp(-dstar*s)+exp(-gamma[i]*s))*(exp(-(dstar+gamma[i])*t)-exp(2*a[1]*t))*(2*a[1]-(dstar+gamma[1]))^-1)
}
#The mean function for I(t)-kN(t) , A(t)
GaussianMean = function(t, C, n,k,d,gamma,lambda,dstar,d1star)
{
ret = (C*d[1]*(dstar-gamma[1])^-1)*(exp(-gamma[1]*t)-exp(-dstar*t))-k*n*exp(-d1star*t)
}
#The covariance function for I(t)-kN(t) , B(t,t)
GaussianVar = function(t, s=0, k, sigma, a, gamma, d, dstar, d1star)
{
CovI(t=t, s=s, sigma=sigma, gamma=gamma, a=a, d=d, dstar=dstar) +
k^2*CovN(t=t,s=s,sigma=sigma,a=a,d1star=d1star)
}
#the following 6 lines are a line by line writeup of the g(t) function and are not important on their
own
#this was done for easier debugging
nl1 = function(t,k,a,sigma,d1star)
{
k^2*sigma[5]^2*(2*(a[5]-d1star))^-1*((2*a[5]-d1star)*exp(-2*a[5]*t)-d1star*exp(2*d1star*t))
}
nl2 = function(t,a,sigma,gamma)
{
sigma[3]^2*(2*(a[3]-gamma[1]))^-1*((2*a[3]-gamma[1])*exp(-2*a[3]*t)-gamma[1]*exp(2*gamma[1]*t))
}
nl3 = function(t,d,a,sigma,gamma,dstar)
{
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(d[1]*sigma[1]*(dstar-gamma[1])^-1)^2*(2*(a[1]-dstar))^-1*((2*a[1]-dstar)*exp(-2*a[1]*t)dstar*exp(-2*dstar*t))
}
nl4 = function(t,d,a,sigma,gamma,dstar)
{
(d[1]*sigma[1]*(dstar-gamma[1])^-1)^2*(2*(a[1]-gamma[1]))^-1*((2*a[1]-gamma[1])*exp(2*a[1]*t)-gamma[1]*exp(-2*gamma[1]*t))
}
nl5 = function(t,d,a,sigma,gamma,dstar)
{
(d[1]*sigma[1]*(dstar-gamma[1])^-1)^2*(2*a[1]-(dstar+gamma[1]))^-1*((2*a[1]-dstar)*exp(2*a[1]*t)-gamma[1]*exp(-(dstar+gamma[1])*t))
}
nl6 = function(t,d,a,sigma,gamma,dstar)
{
(d[1]*sigma[1]*(dstar-gamma[1])^-1)^2*(2*a[1]-(dstar+gamma[1]))^-1*((2*a[1]gamma[1])*exp(-2*a[1]*t)-dstar*exp(-(dstar+gamma[1])*t))
}
#Derivative of A
ADeriv = function(t,C,n,k,d,gamma,lambda,dstar,d1star)
{
C*d[1]*(dstar-gamma[1])^-1*(-gamma[1]*exp(-gamma[1]*t) + dstar*exp(-dstar*t)) +
k*n*d1star*exp(-d1star*t)
}
#the g function used in the pdf , g(t)
gfunction = function(t,C,n,k,d,a,sigma,lambda,gamma,dstar,d1star)
{
ret = -GaussianMean(t=t,C=C,n=n,k=k,d = d,gamma = gamma,lambda = lambda,dstar =
dstar,d1star = d1star)*
GaussianVar(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,dstar = dstar,d1star
= d1star)^-1*
(nl1(t=t,k = k,a=a,sigma=sigma,d1star=d1star)+
nl2(t=t,a=a,sigma=sigma,gamma=gamma)+
nl3(t=t,d=d,a=a,sigma=sigma,gamma=gamma,dstar=dstar)+
nl4(t=t,d=d,a=a,sigma=sigma,gamma=gamma,dstar=dstar)nl5(t=t,d=d,a=a,sigma=sigma,gamma=gamma,dstar=dstar)nl6(t=t,d=d,a=a,sigma=sigma,gamma=gamma,dstar=dstar))+
ADeriv(t=t,C = C,n = n,k = k,d = d,gamma = gamma,lambda = lambda,dstar = dstar,d1star =
d1star)
ifelse(ret >= 0, ret,0) # fix for tail behavior
}
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# The pdf of the model.
GaussianProbability = function(t,C,n,k,d,a,sigma,lambda,gamma,dstar,d1star)
{
ret=gfunction(t=t,C=C,n = n,k = k,d = d,a = a,sigma = sigma,lambda = lambda,gamma =
gamma,dstar = dstar,d1star = d1star)*
(2*pi*GaussianVar(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,dstar =
dstar,d1star = d1star))^(-.5)*
exp(-.5*GaussianMean(t = t,C = C,n = n,k = k,d = d,gamma = gamma,lambda = lambda,dstar
= dstar,d1star = d1star)^2*
GaussianVar(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,dstar =
dstar,d1star = d1star)^-1)
}
#vector version of the integral of the pdf of the model
pfunc = function(t,lower=1e-100,C,n,k,a,sigma,d,gamma,lambda,dstar,d1star)
{
integrate(GaussianProbability,lower=lower,upper=t,C=C,n=n,k=k,a=a,sigma=sigma,d=d,gamma
=gamma,lambda=lambda,dstar=dstar,d1star=d1star)$value
}
pfunc.v = Vectorize(pfunc,"t")
# The expected value of t given the parameters under the assumptions of the model
GaussianExpectedValue = function(t,C,n,k,d,aval,sigma,lambda,gamma,dstar,d1star)
{
ret = t*gfunction(t=t,C=C,n = n,k = k,d = d,a = aval,sigma = sigma,lambda = lambda,gamma =
gamma,dstar = dstar,d1star = d1star)*
(2*pi*GaussianVar(t = t,s = 0,k = k,sigma = sigma,a = aval,gamma = gamma,d = d,dstar =
dstar,d1star = d1star))^(-.5)*
exp(-.5*GaussianMean(t = t,C = C,n = n,k = k,d = d,gamma = gamma,lambda = lambda,dstar =
dstar,d1star = d1star)^2*
GaussianVar(t = t,s = 0,k = k,sigma = sigma,a = aval,gamma = gamma,d = d,dstar =
dstar,d1star = d1star)^-1)
}
#Badfunction basically finds the end points of the distribution and truncates them because
strange things happen at the tails
#It is called bad function because it is slow and bad.
Badfunction = function(C,n,k,d,a,sigma,lambda,gamma,dstar,d1star,tolerance=1e3,byincrease=.01,start.at=0,max_iterations=10000)
{
#initialize variables. I don't know if we have to do this in R but in C++ we do so there. Also
nick, remember not to put ;
CurNumber = 0
firstFound = FALSE
Iternumber = start.at #start here. Hopefully we'd start somewhere around the expectation we
want - some epsilon.
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#starting at 0 in some cases can make this take a very long time.
lower = 0
upper = 0
iteration = 0
#while we haven't hit the max number of iterations we want and we have a finite CurNumber
while((is.nan(CurNumber) | CurNumber<Inf) & iteration < max_iterations)
{
CurNumber =
GaussianExpectedValue(t=Iternumber,C=C,n=n,k=k,d=d,a=a,sigma=sigma,lambda=lambda,gam
ma=gamma,dstar=dstar,d1star=d1star)
try(if(is.infinite(CurNumber)) stop("Badfunction - CurNumber is infinite. This is bad."))
if(!is.nan(CurNumber) & (CurNumber > tolerance & firstFound==FALSE))
{
lower=Iternumber
firstFound=TRUE
}
else if(CurNumber <= tolerance & firstFound==TRUE)
{
upper=Iternumber
break; #bad programming practice =)
}
Iternumber=Iternumber+byincrease #number here to find out where we should go.
iteration=iteration+1
}
try(if(iteration >= max_iterations) stop("Max iterations reached in BadFunction"))
list("lower"=lower,"upper"=upper) #return our lower and upper integration sections. If
tolerance is chosen well it shouldn't cause a large difference
}
#vectorizing the funcions, might be useful for speed increase of algorithm
#will test this out later
hfunc =
function(lint=0,uint=Inf,C,n,k,a,sigma,d,gamma,lambda,dstar,d1star)#,TruncateWindow=c(0,5),t
olerance = 1e-3)
{
integrate(GaussianExpectedValue,lower=lint,upper=uint,C=C,n=n,k=k,aval=a,sigma=sigma,d=d
,gamma=gamma,lambda=lambda,dstar=dstar,d1star=d1star)$value
}
zfunc = Vectorize(hfunc,"C")
#this is the test function to integrate within the bounds we set up.
testfunc = function(C,n,k,a,sigma,d,gamma,lambda,dstar,d1star,tolerance=1e3,start.at=0,max_iterations=10000,bounds.increaseby=.01)
{
bounds = Badfunction(C = C,n = n,k = k,d = d,a = a,sigma = sigma,lambda = lambda,gamma =
gamma,dstar = dstar,d1star = d1star,tolerance=tolerance,start.at=start.at,max_iterations =
max_iterations,byincrease = bounds.increaseby)
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integrate(GaussianExpectedValue,lower=bounds$lower,upper=bounds$upper,C=C,n=n,k=k,aval
=a,sigma=sigma,d=d,gamma=gamma,lambda=lambda,dstar=dstar,d1star=d1star)$value
}
testfunc.v = Vectorize(testfunc,"C")
#the algorithm proposed by ebrihimi et al based on a frequentist framework with a slight
modification for increments.
AlgFrequentist =
function(alpha,Cstart,n,k,a,sigma,d,gamma,lambda,start.at=0,max_iterations=1e99,max_bounds
_iterations=1e4,tolerance=1e-3,bounds.increaseby=.01,increment = 1)
{
FD=FALSE #first iteration done
LT=FALSE #less than or greater than handler.
C = Cstart #what we start at
currentT=Inf #no matter what this is going to start somewhere, just use infinity.
iteration = 0
#Integrated=0
dstar=d[1]+d[2]+d[3]
d1star=lambda[1]-lambda[2]
#find where to truncate the pdf because of tail behavior. We know that p(t) will be increasing
with C so we only need to find this once
while(iteration <= max_iterations)
{
#Previous inetgral
PrevIntegrate = currentT
#Expected Value
currentT = testfunc.v(C = C,n = n,k = k,a = a,sigma = sigma,d = d,gamma = gamma,lambda =
lambda,dstar = dstar,d1star = d1star,tolerance = tolerance,start.at =start.at,max_iterations =
max_bounds_iterations,bounds.increaseby=bounds.increaseby)
#this is the value of the integral
#if less than, we're going to be subtracting nanoconjugates
if(currentT < alpha)
{
if(FD==TRUE && LT==FALSE) #we were above alpha, now we're below.
{
C=C+increment
#return our C, our current time, and the integrand stuff
break
}
FD=TRUE
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LT=TRUE
C=C-increment
}
#greater than means adding nanoconjugates
else if(currentT > alpha)
{
if(FD==TRUE && LT==TRUE) # we were below alpha now we're above
{
C=C-increment
#return our C, our current time, and the integrand stuff
break
}
FD=TRUE
LT=FALSE
C=C+increment
}
#if it's equal, we did it perfectly, this is very unlikely (p(this) = 0) but if it happens we're done
else if(currentT==alpha)
{
FD=TRUE
#return our C, our current time, and the integrand stuff
break
}
try(if(C < n*k) stop("Something broke, C < n*k, this is impossible based on this models
assumptions. It is likely that alpha is set too high"))
iteration=iteration+1
}
if(increment > 1)
{
increment = increment/10
AlgFrequentist(alpha = alpha,Cstart = C,n = n,k = k,a = a,sigma = sigma,d = d,gamma =
gamma,lambda = lambda,start.at = start.at,max_iterations =
max_iterations,max_bounds_iterations = max_bounds_iterations,tolerance =
tolerance,bounds.increaseby = bounds.increaseby,increment = increment)
}
else
list("Expected Nanoconjugates" = C,"Expected Time Units" = PrevIntegrate,"Current
Integral" = currentT, "Previous Integral"= PrevIntegrate, iteration=iteration)
}
ntest = 210
atest=c(.142,0,.0144,0,.177)
sigmatest=c(.5,0,.61,0,.44)
gammatest=c(1.2,.006)
dtest=c(1.2,.1,.1)
lambdatest=c(.81,.2)
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tolerancetest=1e-15
start.at.test=0
increase.by.test=.001
ktest=5
ex1.5.1tu = AlgFrequentist(alpha = 1,Cstart = 1750,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e3,max_bounds_iterations = 1e5,bounds.increaseby =
increase.by.test,increment = 10)
ex1.5.halftu = AlgFrequentist(alpha = .5,Cstart = 2050,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 10)
ktest=10
ex1.10.1tu = AlgFrequentist(alpha = 1,Cstart = 4050,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 100)
ex1.10.halftu = AlgFrequentist(alpha = .5,Cstart = 4050,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 100)
ktest=15
ex1.15.1tu = AlgFrequentist(alpha = 1,Cstart = 8000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 100)
ex1.15.halftu = AlgFrequentist(alpha = .5,Cstart = 8000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 100)
ktest=20
ex1.20.1tu = AlgFrequentist(alpha = 1,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ex1.20.halftu = AlgFrequentist(alpha = .5,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
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ktest=25
ex1.25.1tu = AlgFrequentist(alpha = 1,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ex1.25.halftu = AlgFrequentist(alpha = .5,Cstart = 14000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ktest=30
ex1.30.1tu = AlgFrequentist(alpha = 1,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ex1.30.halftu = AlgFrequentist(alpha = .5,Cstart = 14000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ktest=5
ex2.5.1tu = AlgFrequentist(alpha = 1,Cstart = 11500,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e50,bounds.increaseby =
increase.by.test,increment = 100)
ex2.5.halftu = AlgFrequentist(alpha = .5,Cstart = 16500,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 100)
ktest=10
ex2.10.1tu = AlgFrequentist(alpha = 1,Cstart = 22500,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=100)
ex2.10.halftu = AlgFrequentist(alpha = .5,Cstart = 32000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 1000)
ktest=15
ex2.15.1tu = AlgFrequentist(alpha = 1,Cstart = 33750,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
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start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex2.15.halftu = AlgFrequentist(alpha = .5,Cstart = 48000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 1000)
ktest=20
ex2.20.1tu = AlgFrequentist(alpha = 1,Cstart = 45000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex2.20.halftu = AlgFrequentist(alpha = 0.5,Cstart = 64000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=25
ex2.25.1tu = AlgFrequentist(alpha = 1,Cstart = 56000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex2.25.halftu = AlgFrequentist(alpha = 0.5,Cstart = 80000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=30
ex2.30.5tu = AlgFrequentist(alpha = 1,Cstart = 66000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex2.30.1tu = AlgFrequentist(alpha = 0.5,Cstart = 96000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=5
ex3.5.1tu = AlgFrequentist(alpha = 1,Cstart = 6000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e50,bounds.increaseby =
increase.by.test,increment = 1000)
ex3.5.halftu = AlgFrequentist(alpha = .5,Cstart = 9000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
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start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment = 1000)
ktest=10
ex3.10.1tu = AlgFrequentist(alpha = 1,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex3.10.halftu = AlgFrequentist(alpha = .5,Cstart = 10000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=15
ex3.15.1tu = AlgFrequentist(alpha = 1,Cstart = 15000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex3.15.halftu = AlgFrequentist(alpha = .5,Cstart = 15000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=20
ex3.20.1tu = AlgFrequentist(alpha = 1,Cstart = 20000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex3.20.halftu = AlgFrequentist(alpha = .5,Cstart = 20000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=25
ex3.25.1tu = AlgFrequentist(alpha = 1,Cstart = 25000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex3.25.halftu = AlgFrequentist(alpha = .5,Cstart = 25000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ktest=30
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ex3.30.1tu = AlgFrequentist(alpha = 1,Cstart = 30000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)
ex3.30.halftu = AlgFrequentist(alpha = .5,Cstart = 30000,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test,increment=1000)

#Chapter 3
Nick_Average =
function(C,n,k,a,sigma,d,gamma,lambda,start.at=0,max_iterations=1e99,max_bounds_iterations
=1e4,tolerance=1e-3,bounds.increaseby=.01,loops=50000)
{
fails=0
n.avg = rpois(loops,n)
k.avg = rpois(loops,k)
d1star = lambda[1]-lambda[2]
a1 = rexp(loops,1/a[1])
a2 = 0
a3 = rexp(loops,1/a[3])
a4 = 0
a5 = rexp(loops,1/a[5])
#a.avg = data.frame(a1,a2,a3,a4,a5)
sigma1 = rexp(loops,1/sigma[1])
sigma2 = 0
sigma3 = rexp(loops,1/sigma[3])
sigma4 = 0
sigma5 = rexp(loops,1/sigma[5])
#sigma.avg = data.frame(sigma1,sigma2,sigma3,sigma4,sigma5)
d1 = rexp(loops,1/d[1])
d2 = rexp(loops,1/d[2])
d3 = rexp(loops,1/d[3])
#d.avg = data.frame(d1,d2,d3)
gamma1 = rexp(loops,1/gamma[1])
gamma2 = rexp(loops,1/gamma[2])
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#gamma.avg = data.frame(gamma1,gamma2)
lambda1 = rexp(loops,1/lambda[1])
lambda2 = rexp(loops,1/lambda[2])
#lambda.avg = data.frame(lambda1,lambda2)
require(smoothmest)
#dstar.avg = rgamma(loops,shape=3,rate=d.avg[1]+d.avg[2]+d.avg[3])
d1star.avg = rdoublex(loops,mu=mean(lambda1),lambda=mean(lambda2))
integrate.vec = numeric(loops) #need this for large factorials
i=1
while(i <= loops)
{
while(d1star.avg[i] < 0)
{
d1star.avg[i] = rdoublex(1,mu=mean(lambda1),lambda=mean(lambda2))
}
while(gamma1[i] > (d1[i]+d2[i]+d3[i]) | gamma2[i] > (d1[i]+d2[i]+d3[i]))
{
gamma1[i] = rexp(1,1/gamma[1])
gamma2[i] = rexp(1,1/gamma[2])
d1[i] = rexp(1,1/d[1])
d2[i] = rexp(1,1/d[2])
d3[i] = rexp(1,1/d[3])
}
integrate.vec[i] = testfuncb(C = C,n = n,k = k,a = c(a1[i],0,a3[i],0,a5[i]),
sigma = c(sigma1[i],0,sigma3[i],0,sigma5[i]),
d = c(d1[i],d2[i],d3[i]),
gamma = c(gamma1[i],gamma2[i]),
d1star = d1star.avg[i],tolerance = tolerance,start.at = start.at,max_iterations =
max_bounds_iterations,bounds.increaseby = bounds.increaseby,
v=c(d[1],d[2],d[3],a[1],a[3],a[5],sigma[1],sigma[3],sigma[5],gamma[1],gamma[2],d1star.avg[i],
n.avg[i],k.avg[i]))
if(integrate.vec[i] == 0) #it failed, resample.
{
fails = fails+1
print(i)
print(a1[i])
print(a3[i])
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print(a5[i])
print(d1[i])
print(d2[i])
print(d3[i])
print(sigma1[i])
print(sigma3[i])
print(sigma5[i])
print(gamma1[i])
print(gamma2[i])
print(d1star.avg[i])
print(fails)
print(fails/i)
try(if(integrate.vec[i]==0) stop("Error converging"))
a1[i] = rexp(1,1/a[1])
a3[i] = rexp(1,1/a[3])
a5[i] = rexp(1,1/a[5])
sigma1[i] = rexp(1,1/sigma[1])
sigma3[i] = rexp(1,1/sigma[3])
sigma5[i] = rexp(1,1/sigma[5])
d1[i] = rexp(1,1/d[1])
d2[i] = rexp(1,1/d[2])
d3[i] = rexp(1,1/d[3])
gamma1[i] = rexp(1,1/gamma[1])
gamma2[i] = rexp(1,1/gamma[2])
d1star.avg[i] = rdoublex(1,mu=mean(lambda1),lambda=mean(lambda2))
n.avg[i] = rpois(1,n)
k.avg[i] = rpois(1,k)
i=i-1
}
i=i+1
}
ret = mean(integrate.vec)
ret
}
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nl1b = function(t,k,a,sigma,d1star)
{
k^2*sigma[5]^2*(2*(a[5]-d1star))^-1*((2*a[5]-d1star)*exp(-2*a[5]*t)-d1star*exp(2*d1star*t))
}
nl2b = function(t,a,sigma,gamma)
{
sigma[3]^2*(2*(a[3]-gamma[1]))^-1*((2*a[3]-gamma[1])*exp(-2*a[3]*t)-gamma[1]*exp(2*gamma[1]*t))
}
nl3b = function(t,d,a,sigma,gamma)
{
(d[1]*sigma[1]*((d[1]+d[2]+d[3])-gamma[1])^-1)^2*(2*(a[1]-(d[1]+d[2]+d[3])))^-1*((2*a[1](d[1]+d[2]+d[3]))*exp(-2*a[1]*t)-(d[1]+d[2]+d[3])*exp(-2*(d[1]+d[2]+d[3])*t))
}
nl4b = function(t,d,a,sigma,gamma)
{
(d[1]*sigma[1]*((d[1]+d[2]+d[3])-gamma[1])^-1)^2*(2*(a[1]-gamma[1]))^-1*((2*a[1]gamma[1])*exp(-2*a[1]*t)-gamma[1]*exp(-2*gamma[1]*t))
}
nl5b = function(t,d,a,sigma,gamma)
{
(d[1]*sigma[1]*((d[1]+d[2]+d[3])-gamma[1])^-1)^2*(2*a[1]-((d[1]+d[2]+d[3])+gamma[1]))^1*((2*a[1]-(d[1]+d[2]+d[3]))*exp(-2*a[1]*t)-gamma[1]*exp(-((d[1]+d[2]+d[3])+gamma[1])*t))
}
nl6b = function(t,d,a,sigma,gamma)
{
(d[1]*sigma[1]*((d[1]+d[2]+d[3])-gamma[1])^-1)^2*(2*a[1]-((d[1]+d[2]+d[3])+gamma[1]))^1*((2*a[1]-gamma[1])*exp(-2*a[1]*t)-(d[1]+d[2]+d[3])*exp(-((d[1]+d[2]+d[3])+gamma[1])*t))
}
gfunctionb = function(t,C,n,k,d,a,sigma,gamma,d1star)
{
ret = -GaussianMeanb(t=t,C=C,n=n,k=k,d = d,gamma = gamma,d1star = d1star)*
GaussianVarb(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,d1star = d1star)^1*
(nl1b(t=t,k = k,a=a,sigma=sigma,d1star=d1star)+
nl2b(t=t,a=a,sigma=sigma,gamma=gamma)+
nl3b(t=t,d=d,a=a,sigma=sigma,gamma=gamma)+
nl4b(t=t,d=d,a=a,sigma=sigma,gamma=gamma)-
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nl5b(t=t,d=d,a=a,sigma=sigma,gamma=gamma)nl6b(t=t,d=d,a=a,sigma=sigma,gamma=gamma))+
ADerivb(t=t,C = C,n = n,k = k,d = d,gamma = gamma,d1star = d1star)
ifelse(ret >= 0, ret,0) # fix for tail behavior
}
CovIb = function(t, s=0, sigma, gamma, a, d,i=1)
{
sigma[i+2]^2*(2*(a[i+2]-gamma[i]))^-1*exp(-gamma[i]*s)*(exp(-2*gamma[i]*t)-exp(2*a[i+2]*t))+
(d[i]*sigma[1]*((d[1]+d[2]+d[3])-gamma[i])^-1)^2*((exp(-2*(d[1]+d[2]+d[3])*t)-exp(2*a[1]*t))*(2*(a[1]-(d[1]+d[2]+d[3])))^-1*exp(-(d[1]+d[2]+d[3])*s)+
(exp(-2*gamma[i]*t)-exp(-2*a[1]*t))*(2*(a[1]-gamma[i]))^-1*exp(gamma[i]*s)(exp(-(d[1]+d[2]+d[3])*s)+exp(-gamma[i]*s))*(exp(((d[1]+d[2]+d[3])+gamma[i])*t)-exp(-2*a[1]*t))*(2*a[1]-((d[1]+d[2]+d[3])+gamma[i]))^-1)
}
GaussianMeanb = function(t, C, n,k,d,gamma,d1star)
{
ret = (C*d[1]*((d[1]+d[2]+d[3])-gamma[1])^-1)*(exp(-gamma[1]*t)-exp(-(d[1]+d[2]+d[3])*t))k*n*exp(-d1star*t)
}
GaussianVarb = function(t, s=0, k, sigma, a, gamma, d, d1star)
{
CovIb(t=t, s=s, sigma=sigma, gamma=gamma, a=a, d=d) +
k^2*CovN(t=t,s=s,sigma=sigma,a=a,d1star=d1star)
}
ADerivb = function(t,C,n,k,d,gamma,d1star)
{
C*d[1]*((d[1]+d[2]+d[3])-gamma[1])^-1*(-gamma[1]*exp(-gamma[1]*t) +
(d[1]+d[2]+d[3])*exp(-(d[1]+d[2]+d[3])*t)) + k*n*d1star*exp(-d1star*t)
}
#nntest = AlgFrequentist(alpha = .5,Cstart = 6150,n = ntest,k = ktest,a = atest,sigma =
sigmatest,d = dtest,gamma = gammatest,lambda = lambdatest,tolerance=tolerancetest,start.at =
start.at.test,max_iterations = 1e6,max_bounds_iterations = 1e4,bounds.increaseby =
increase.by.test)
GaussianProbabilityb = function(t,C,n,k,d,a,sigma,gamma,d1star,v)
{
gfunctionb(t=t,C=C,n = n,k = k,d = d,a = a,sigma = sigma,gamma = gamma,d1star = d1star)*
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(2*pi*GaussianVarb(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,d1star =
d1star))^(-.5)*
exp(-.5*GaussianMeanb(t = t,C = C,n = n,k = k,d = d,gamma = gamma,d1star = d1star)^2*
GaussianVarb(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,d1star =
d1star)^-1)
}
GaussianExpectedValueb =
function(t,C,n,k,d,a,sigma,gamma,d1star,v=c(d[1],d[2],d[3],a[1],a[3],a[5],sigma[1],sigma[3],sig
ma[5],gamma[1],gamma[2],d1star))
{
t*gfunctionb(t=t,C=C,n = n,k = k,d = d,a = a,sigma = sigma,gamma = gamma,d1star = d1star)*
(2*pi*GaussianVarb(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,d1star =
d1star))^(-.5)*
exp(-.5*GaussianMeanb(t = t,C = C,n = n,k = k,d = d,gamma = gamma,d1star = d1star)^2*
GaussianVarb(t = t,s = 0,k = k,sigma = sigma,a = a,gamma = gamma,d = d,d1star =
d1star)^-1)
}
testfuncb = function(C,n,k,a,sigma,d,gamma,d1star,v,tolerance=1e3,start.at=0,max_iterations=10000,bounds.increaseby=.01)
{
ret = 0
ret1 = 0
ret2 = 0
bounds = Badfunctionb(C = C,n = n,k = k,d = d,a = a,sigma = sigma,gamma = gamma,d1star =
d1star,v=v,tolerance=tolerance,start.at=start.at,max_iterations = max_iterations,byincrease =
bounds.increaseby)
if(bounds$converged == TRUE)
ret1 =
integrate(GaussianExpectedValueb,lower=bounds$lower,upper=bounds$upper,C=C,n=n,k=k,a=
a,sigma=sigma,d=d,gamma=gamma,d1star=d1star,v=v)$value
if(ret1 != 0)
{
ret2 =
integrate(GaussianProbabilityb,lower=bounds$lower,upper=bounds$upper,C=C,n=n,k=k,a=a,sig
ma=sigma,d=d,gamma=gamma,d1star=d1star,v=v)$value
ret = ret1/ret2
}
ret
}
testfuncb.v = Vectorize(testfuncb,"C")
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Badfunctionb = function(C,n,k,d,a,sigma,gamma,d1star,v,tolerance=1e3,byincrease=.01,start.at=0,max_iterations=10000)
{
#initialize variables. I don't know if we have to do this in R but in C++ we do so there. Also
nick, remember not to put ;
CurNumber = 0
firstFound = FALSE
converged = FALSE
Iternumber = start.at #start here. Hopefully we'd start somewhere around the expectation
#starting at 0 in some cases can make this take a very long time.
lower = 0
upper = 0
iteration = 0
#while we haven't hit the max number of iterations we want and we have a finite CurNumber
while((is.nan(CurNumber)| is.na(CurNumber) | CurNumber<Inf) & iteration < max_iterations)
{
CurNumber =
GaussianExpectedValueb(t=Iternumber,C=C,n=n,k=k,d=d,a=a,sigma=sigma,gamma=gamma,d1
star=d1star,v=v)
try(if(is.infinite(CurNumber)) stop("Badfunction - CurNumber is infinite. This is bad."))
if(!is.nan(CurNumber) & !is.na(CurNumber) & (CurNumber > tolerance &
firstFound==FALSE))
{
lower=Iternumber
firstFound=TRUE
}
else if(CurNumber <= tolerance & firstFound==TRUE)
{
upper=Iternumber
converged = TRUE
break; #bad programming practice =)
}
Iternumber=Iternumber+byincrease #number here to find out where we should go.
iteration=iteration+1
}
try(if(iteration >= max_iterations) stop("Max iterations reached in BadFunction"))
list("lower"=lower,"upper"=upper,"converged"=converged) #return our lower and upper
integration sections. If tolerance is chosen well it shouldn't cause a large difference
}
ex1.50000i.c1743 = Nick_Average(C = 1743,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
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ex1.50000i.c1800 = Nick_Average(C = 1800,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
ex1.50000i.c1850 = Nick_Average(C = 1850,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
ex1.50000i.c1900 = Nick_Average(C = 1900,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
ex1.50000i.c1950 = Nick_Average(C = 1950,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
ex1.50000i.c2000 = Nick_Average(C = 2000,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)
ex1.50000i.c2050 = Nick_Average(C = 2050,n = 5,k = ktest,a = atest,sigma = sigmatest,d =
dtest,gamma = gammatest,lambda = lambdatest,start.at = start.at.test,bounds.increaseby =
.001,loops = 50000,max_bounds_iterations = 1e5,tolerance = 1e-15)

